Novo Nordisk (NVO) said Wednesday it is offering cash-paying patients all dose strengths of Wegovy at a lower price of $499 per month through a direct-to-patient delivery option called NovoCare Pharmacy.
The company said NovoCare Pharmacy expands its offerings to meet the needs of people living with obesity, following the recent decision of the US Food and Drug Administration that the shortage of the medicine has been resolved.
Uninsured patients or eligible patients with commercial insurance who don't have coverage for obesity medicines can avail of the offer, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。